


*The Pediatric Combination
that lasts*



PERFORMANCE through experience



PROPATEN®


VASCULAR GRAFT



A New Category *in Pediatric Shunts*

- ▶ Gore builds on proven elements you can trust — a combination of innovation and a history of clinical success.
- ▶ **More than 400,000** successful GORE® PROPATEN® Vascular Graft implants and more than four decades of experience with GORE-TEX® Vascular Graft configured for Pediatric Shunts worldwide.
- ▶ **More than 400** scientific papers including numerous clinical studies have demonstrated the performance of the CBAS Heparin Surface.
- ▶ **More than 40 million** Gore clinical ePTFE implants worldwide.
- ▶ **More than 40 years** of experience in medical device implants.

PROPRIETARY COVALENT END-POINT BONDING



CBAS HEPARIN SURFACE
LASTING
THROMBORESISTANCE
PROVEN
TECHNOLOGY

Covalent end-point bonding allows the heparin to extend into the bloodstream, keeping the active site bioavailable, unlike a non-permanent bond that can be washed away in the bloodstream.

- The anticoagulant function of heparin is dependent on the bioavailability of an active site within the molecule
- Some methods of covalent heparin bonding damage and / or obstruct the active site, and hence destroy heparin's anticoagulant activity
- The CBAS Heparin Surface of the GORE® PROPATEN® Vascular Graft consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin's anticoagulant activity

HEPARIN

- A proven anticoagulant
- Derived from heparin sourced in North America
- Reduced molecular weight heparin of porcine origin

ePTFE

- Unchanged GORE-TEX® Vascular Graft handling properties




Relaxed State



*Moderate Tension for
Implantation*

Stretch Technology



*Longitudinal extensibility –
allowing easier tailoring
and sizing*



*Kink resistance – improved
handling, soft and supple while
enhancing kink resistance*

CATALOGUE NUMBER*	INTERNAL DIAMETER (mm)	GRAFT LENGTH (cm)
HPT030005A	3	5
HPT030010A	3	10
HPT030015A	3	15
HPT350005A	3.5	5
HPT350010A	3.5	10
HPT350015A	3.5	15
HPT040005A	4	5
HPT040010A	4	10
HPT040015A	4	15
HPT050005A	5	5
HPT050010A	5	10
HPT050015A	5	15
HPT060015A	6	15

* European catalogue numbers do not include the 'A'.

For additional sizes and catalogue numbers, please call your local Gore Sales Representative.

Aquilant

A HC21 Company

csuk@hc21.group

01256 306506

healthcare21.eu



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc. GORE®, GORE-TEX®, PROPATEN®, PERFORMANCE THROUGH EXPERIENCE, and designs are trademarks of W. L. Gore & Associates.

© 2010, 2016 W. L. Gore & Associates, Inc. AP0059-EN5 OCTOBER 2016

Examples of Applications in Pediatric Cardiac Surgery:

- Complex Tetralogy of Fallot¹⁻⁴
- Pulmonary atresia with VSD²⁻⁴
- Pulmonary atresia with intact septum²⁻⁴
- Double outlet right ventricle with pulmonary stenosis^{2,4}
- Complete transposition with pulmonary stenosis²⁻⁴
- HLHS and other single ventricle equivalents^{2,4,5}

1. Alkhulaifi AM, Lacour-Gayet F, Serraf A, Belli E, Planché C. Systemic pulmonary shunts in neonates: early clinical outcome and choice of surgical approach. *Annals of Thoracic Surgery* 2000;69(5):1499-1504.
1. Ishino K, Stümper O, De Giovanni JJ, et al. The modified Norwood procedure for hypoplastic left heart syndrome: early to intermediate results of 120 patients with particular reference to aortic arch repair. *Journal of Thoracic & Cardiovascular Surgery* 1999;117(5):920-930.
2. Gladman G, McCrindle BW, Williams WG, Freedom RM, Benson LN. The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot's tetralogy in the current era. *Journal of Thoracic & Cardiovascular Surgery* 1997;114(1):25-30.
3. Tsai KT, Chang CH, Lin PJ. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. *Journal of Cardiovascular Surgery* 1996;37(2):149-152.
4. Al Jubair KA, Al Fagih MR, Al Jarallah AS, et al. Results of 546 Blalock-Taussig shunts performed in 478 patients. *Cardiology in the Young* 1998;8(4):486-490.